Fractyl Health Secures US Patent for Revita Catheter With Protection Through 2042

PUBT · 2d ago
Fractyl Health Secures US Patent for Revita Catheter With Protection Through 2042
  • Fractyl Health received a U.S. patent covering Revita catheter design features on September 22, 2026, strengthening protection for its investigational treatment.
  • The catheter patent extends to November 28, 2042; existing duodenal treatment-method claims are not limited to a specific energy modality.
  • The U.S. Patent and Trademark Office also allowed an application covering Revita's thermal dosing method.
  • Revita is advancing toward a planned FDA De Novo marketing submission for post-GLP-1 weight maintenance following positive six-month REMAIN-1 pivotal results.
  • The portfolio includes 39 granted U.S. patents, approximately 40 pending U.S. applications and more than 50 issued international patents.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300700PRIMZONEFULLFEED9856738) on October 30, 2026, and is solely responsible for the information contained therein.